||A labelled form of Tenofovir alafenamide fumarate. Tenofovir alafenamide fumarate, also known as Tenofovir alafenamide hemifumarate. TAF, GS-7340, is a nucleotide reverse transcriptase inhibitor and a novel prodrug of tenofovir. It is under development by Gilead Sciences for use in the treatment of HIV infection. Closely related to the commonly used reverse-transcriptase inhibitor tenofovir disoproxil fumarate (Viread), Tenofovir alafenamide has greater antiviral activity and better distribution into lymphoid tissues than that agent. Gilead has announced a phase 3 clinical trial evaluating a single-tablet regimen combining GS-7340 with cobicistat, emtricitabine and elvitegravir and plans to coformulate the drug with cobicistat, emtricitabine and the protease inhibitor darunavir.
||GS 7171-d5 Fumarate; 1-Methylethyl Ester N-[[[(1R)-2-(6-Amino-9H-purin-9-yl)-1-methylethoxy]methyl]phenoxyphosphinyl]-L-alanine-d5 Fumarate
||Soluble in DMSO, Methanol
||White to Off-white Solid
||Hygroscopic, Store at -20°C, Under inert atmosphere